skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron

Review

(3632) Views  (1149) Full article downloads

Authors: Emilio Bajetta, Sara Pusceddu, Valentina Guadalupi, et al

Published Date August 2009 Volume 2009:1 Pages 89 - 97
DOI: http://dx.doi.org/10.2147/CMAR.S4739

Emilio Bajetta, Sara Pusceddu, Valentina Guadalupi, Monika Ducceschi, Luigi Celio

Medical Oncology Unit 2, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy

Abstract: Prevention of nausea and vomiting is the main goal of antiemetic treatment in cancer patients scheduled to receive chemotherapy. To prevent acute emesis, antiemetics should be administered just before chemotherapy and patients should be protected for up to 24 hours after chemotherapy initiation. The emetogenic potential of chemotherapeutic agents guides clinicians towards the most appropriate antiemetic prophylaxis. Current guidelines recommend the use of 5-HT3 receptor antagonist (RA) either alone or in combination with dexamethasone and/or a neurokinin-1 RA both in the acute and delayed phases. The second-generation 5-HT3RA palonosetron exhibits a longer half-life and a higher binding affinity than older antagonists. Palonosetron has been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients scheduled to receive either moderately (MEC) or highly emetogenic chemotherapy (HEC) and for the prevention of delayed CINV in patients receiving MEC. The present review will discuss the role of palonosetron in the prevention of acute CINV.

Keywords: antiemetics, chemotherapy, nausea, vomiting, serotonin-receptor antagonists, palonosetron








Readers of this article also read:

Palonosetron as an anti-emetic and anti-nausea agent in oncology
Management of postoperative nausea and vomiting: focus on palonosetron
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University